Clinical trials: Pomalidomide
Multiple Myeloma
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
This is a multicenter, open-label, Phase 1b study to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with POM with or without low dose dex in subjects with RRMM.
- Trial name
- NCT02616640
- Testing
- Durvalumab, Pomalidomide, Dexamethasone
- Where
- 22 sites in United States, Canada and 5 more
- Volunteers
- 114 people
- Sponsor
- Celgene
Relapsed and/or Refractory Multiple Myeloma
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma.
- Trial name
- NCT03170882
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- 111 sites in United States, Australia and 16 more
- Volunteers
- 122 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy Volunteers
Food Effect and CYP1A2 Induction Study in Healthy Subjects
This study will evaluate the effect of food and smoking on healthy older subjects taking pomalidomide.
- Trial name
- NCT02168205
- Testing
- Pomalidomide, Caffeine, Tobacco
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma…
- Trial name
- STOMP (NCT02343042)
- Testing
- Selinexor, Dexamethasone, Lenalidomide
- Where
- 25 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Karyopharm Therapeutics Inc
Healthy
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.
- Trial name
- NCT01474330
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
- Trial name
- NCT03539744
- Testing
- Pomalidomide, Dexamethasone, Venetoclax
- Where
- 180 sites in United States, Australia and 18 more
- Volunteers
- 265 people
- Sponsor
- AbbVie
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and…
- Trial name
- DOMMINO-1 (NCT07096778)
- Testing
- Inobrodib, Pomalidomide, Dexamethasone
- Where
- 31 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- CellCentric Ltd.
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain…
- Trial name
- NCT07728188
- Testing
- Etentamig, Pomalidomide, Daratumumab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory…
- Trial name
- SUCCESSOR-1 (NCT05519085)
- Testing
- mezigdomide, Pomalidomide, Bortezomib
- Where
- 266 sites in United States, Argentina and 27 more
- Volunteers
- 810 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have…
- Trial name
- NCT02431208
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that…
- Trial name
- LINKER-MM3 (NCT05730036)
- Testing
- Linvoseltamab, Elotuzumab, Pomalidomide
- Where
- 159 sites in United States, Australia and 16 more
- Volunteers
- 410 people
- Sponsor
- Regeneron Pharmaceuticals
Plasma Cell Myeloma
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone…
- Trial name
- ICARIA-MM (NCT02990338)
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 111 sites in United States, Australia and 22 more
- Volunteers
- 307 people
- Sponsor
- Sanofi
Relapsed or Refractory Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT07138209
- Testing
- QLS32015, Pomalidomide, Selinexor
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Multiple Myeloma
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose…
- Trial name
- NCT02654132
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia or other B-cell lymphomas.
- Trial name
- NCT02900716
- Testing
- DTRMWXHS-12, DTRM-505, DTRM-555
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Zhejiang DTRM Biopharma
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide…
- Trial name
- MonumenTAL-6 (NCT06208150)
- Testing
- Talquetamab, Pomalidomide, Teclistamab
- Where
- 242 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with…
- Trial name
- NCT02188368
- Testing
- POM, Steroids, PLD
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline